In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum

被引:22
|
作者
Rhomberg, PR
Jones, RN [1 ]
机构
[1] JMI Labs, JONES Grp, N Liberty, IA 52317 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
D O I
10.1016/S0732-8893(01)00332-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In vitro activities of I I antimicrobial agents were determined using Etest (AB BIODISK, Solna, Sweden) against 37 clinical isolates of Mycobacterium marinum, The most potent agent (MIC50. 0.047 mug/mL) was trimethoprim/sulfamethoxazole, but only 91.9% would be categorized as susceptible. Several agents had a complete spectrum of activity including gatifloxacin (MIC90. 0.38 mug/mL), minocycline (MIC90. 2 mug/mL), tetracycline (MIC90, 2 mug/mL) and amikacin (MIC90. 3 mug/mL). The new glycylcycline, GAR936, had a similar potency (MIC90. 3 mug/mL) to that of the parent minocycline compound (MIC90. 2 mug/mL), but the range of MIC values extended to 24 mug/mL. Numerous options appear to exist for the contemporary therapy of M. marinum infections including some newer fluoroquinolones and derivatives of tetracycline (doxycycline, minocycline, GAR936). (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:145 / 147
页数:3
相关论文
共 50 条
  • [1] Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates
    Hayward, CL
    Erwin, ME
    Barrett, MS
    Jones, RN
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 34 (02) : 99 - 102
  • [2] Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates
    Gales, AC
    Jones, RN
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) : 19 - 36
  • [3] In Vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates
    Cercenado, E
    Cercenado, S
    Bouza, E
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) : 2644 - 2645
  • [4] Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus
    Low, DE
    Kreiswirth, BN
    Weiss, K
    Willey, BM
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (03) : 220 - 222
  • [5] Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia
    Betriu, C
    Rodríguez-Avial, I
    Sánchez, BA
    Gómez, M
    Picazo, JJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) : 758 - 759
  • [6] In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates
    Siran Lin
    Wenya Hua
    Shiyong Wang
    Yu Zhang
    Xinchang Chen
    Hong Liu
    Lingyun Shao
    Jiazhen Chen
    Wenhong Zhang
    [J]. BMC Microbiology, 22
  • [7] In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates
    Lin, Siran
    Hua, Wenya
    Wang, Shiyong
    Zhang, Yu
    Chen, Xinchang
    Liu, Hong
    Shao, Lingyun
    Chen, Jiazhen
    Zhang, Wenhong
    [J]. BMC MICROBIOLOGY, 2022, 22 (01)
  • [8] In vitro activity of 12 antimicrobial peptides against Mycobacterium tuberculosis and Mycobacterium avium clinical isolates
    Portell-Buj, Elena
    Vergara, Andrea
    Alejo, Izaskun
    Lopez-Gavin, Alexandre
    Rosa Monte, Maria
    San Nicolas, Lorena
    Gonzalez-Martin, Julian
    Tudo, Griselda
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2019, 68 (02) : 211 - 215
  • [9] In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections
    Fritsche, TR
    Kirby, JT
    Jones, RN
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (03) : 201 - 209
  • [10] In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients
    Rolston, KVI
    Vaziri, I
    Frisbee-Hume, S
    Streeter, H
    LeBlanc, B
    [J]. CHEMOTHERAPY, 2004, 50 (05) : 214 - 220